{"id":23803,"date":"2013-10-01T09:07:11","date_gmt":"2013-10-01T09:07:11","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=23803"},"modified":"2013-10-01T16:57:27","modified_gmt":"2013-10-01T16:57:27","slug":"agreement-to-develop-long-acting-rilpivirine-as-prep","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/23803","title":{"rendered":"Agreement to develop long-acting rilpivirine as PrEP"},"content":{"rendered":"<p><strong>On 25 September 2013, Janssen announced that it had signed a license agreement with international nonprofit health organisation PATH for early stage research to develop a long acting depot formulation of rilpivirine as a potential pre-exposure prophylaxis (PrEP) against HIV.<\/strong> [1]<\/p>\n<p>PATH is planning to collaborate with partners including the HIV Prevention Trials Network for future research for these initial phase 2 studies, and this initiative is funded by the Bill &amp; Melinda Gates Foundation. [2]<\/p>\n<p>Rilpivirine is an NNRTI currently licensed as an oral drug in ARV treatment-na\u00efve adults with a viral load less than or equal to 100,000 copies\/mL and is coformulated with tenofovir\/FTC in the fixed dose combination Eviplera (Edurant in the US).<\/p>\n<p>References:<\/p>\n<ol>\n<li>Jannsen press statement. Janssen R&amp;D Ireland announces agreement with PATH for early development of rilpivirine in long-acting formulation for potential prophylactic intervention, (25 September 2013).<\/li>\n<li>PATH press release. New partnership advances drug formulation that could help prevent HIV infection, (25 September 2013).<br \/>\n<a href=\"http:\/\/www.path.org\/news\/press-room\/647\">http:\/\/www.path.org\/news\/press-room\/647<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>On 25 September 2013, Janssen announced that it had signed a license agreement with international nonprofit health organisation PATH for early stage research to develop a long acting depot formulation of rilpivirine as a potential pre-exposure prophylaxis (PrEP) against HIV. &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-23803","post","type-post","status-publish","format-standard","hentry","category-transmission-and-prevention"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/23803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=23803"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/23803\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=23803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=23803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=23803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}